hepatocellular carcinoma
Conditions
Interventions
the experimental group:TACE using lipiodol followed by TAGM
the control group:TACE using lipiodol followed by gelatin sponge
Sponsors
Fujian Provincial Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Men and female older than 18 years of age; 2. HCC diagnosed by high serum alpha-fetoprotein (AFP more than 400ng/ml) with typical imaging findings, or needle liver biopsy while AFP less than at least 400ng/ml; 3. Impossible to resect; 4. Total bilirubin less than 3*upper limit of normal; 5. Child-Pugh stage A or B; 6. Without extrahepatic metastasis; 7. INR/PTT less than 1.5*upper limit of normal; 8. Written informed consent; 9. ECOG performance status 0-2; 10. Tumor to liver volume ratio(TTLVR) less than 70%; 11. BCLC stage B or C; 12. Expected lifetime more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Prior systemic anticancer therapy; 2. Significant cardiovascular disease such as myocardial infarction less than 6 months previously, chronic heart failure or unstable coronary artery disease; 3. Infiltrative or diffuse HCC; 4. Patients with other malignant tumor within the past 5 years prior to treatment; 5. Pregnant or breastfeeding patients; 6. Patients with uncontrolled infections or HIV seropositive patients; 7. Prior organ transplant; 8. Patients with hemorrhage/bleeding event; 9. Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study; 10. Patients with portal vein thrombosis in the main trunk; 11. Child-Pugh stage C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TTP; | — |
Countries
China
Contacts
Public ContactHai-lan Lin
Outcome results
None listed